U
CARM

UBS’s Carisma Therapeutics CARM Stock Holding History

UBS’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-27
Closed -$7K – 10380
2014
Q2 		$7K Buy
+27
New +$6.68K ﹤0.01% 9201

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

UBS's CARM Position: Q3 2014 in Review

UBS sold out of Carisma Therapeutics (CARM) in Q3 2014, closing a stake of 27 shares — an estimated $7K sold.

UBS first reported a position in CARM in Q2 2014 and held it in 1 quarter. The position peaked at $7K in Q2 2014. 42 funds tracked by Wall St. Rank hold CARM as of Q3 2014.

  • UBS reported no remaining Carisma Therapeutics position as of Q3 2014 after selling out during the quarter.
  • UBS sold 27 Carisma Therapeutics shares in Q3 2014, an estimated $7K.
  • UBS first reported a position in Carisma Therapeutics in Q2 2014 and held it in 1 quarter.
  • UBS's Carisma Therapeutics position peaked at $7K in Q2 2014.
  • 42 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.